Anbio Biotechnology Annual Report - How They Did This Year

I’ve put together this guide to help you understand Anbio Biotechnology’s performance. My goal is to explain their complex filings in plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Anbio Biotechnology operates in the medical testing market, designing and supplying tools that labs and clinics use to diagnose health conditions.

They function as a holding company with a "prepaid" business model: they collect payment from customers before paying outside manufacturers to produce the goods. This approach keeps their internal cash requirements low, but it ties their operational success directly to the performance of their manufacturing partners.

2. Financial performance

Anbio went public on the NASDAQ in February 2025, raising $8 million through the sale of 2 million shares at $4.00 each.

The company is currently navigating a major shift in its business model:

• Transitioning from COVID-19: In 2023, COVID-19 and respiratory tests accounted for 60% of sales. By 2025, that figure dropped to 19.6%, with other diagnostic tests now making up over 80% of revenue. Total revenue for 2024 reached approximately $18.5 million.
• Customer Concentration: The company relies on a small client base. In 2025, two customers accounted for nearly 47% of total revenue. While this is an improvement over previous years, the loss of a single major client could significantly impact the company’s bottom line.

3. Major wins and challenges

• Structural Overhaul: The company recently established "Anbio Samoa" to serve as its primary design and supply hub, a move intended to streamline international tax and operational management.
• Ownership Structure: Two investors—CVC Investment and Northwestern Investment—hold nearly all voting rights, with 49.61% each. This concentration means that individual shareholders have limited influence over board decisions, executive compensation, or long-term corporate strategy.

4. Key risks

Investing in Anbio involves several specific challenges:

• Market Competition: The company competes against established industry leaders like Roche, Abbott, and Siemens. Because hospitals and clinics are often hesitant to switch from trusted, long-term brands, Anbio faces a difficult path to gaining market share.
• Reliance on Outsourced Manufacturing: Anbio does not own its factories. In 2025, they relied on only two suppliers for 100% of their product output. Any disruption at these facilities could halt Anbio’s ability to deliver products.
• The Reimbursement Hurdle: In the U.S., the company’s success depends on whether insurance companies and government programs agree to cover the cost of their tests. Without this coverage, adoption by healthcare providers remains unlikely.
• Inventory Management: Their products have a shelf life of 12 to 24 months. If the company miscalculates demand, they risk holding expired, worthless inventory, which directly reduces their profitability.

5. Future outlook

Anbio’s future depends on its ability to sustain growth beyond the pandemic-era demand. Their strategy focuses on securing regulatory approval for new heart and metabolic health tests. To maintain cash flow, they are prioritizing expansion into markets with faster regulatory pathways, such as Southeast Asia and the Middle East. Their path to profitability relies on scaling these new product lines to offset their operational costs.

Investor Takeaway: When considering this stock, weigh whether you are comfortable with a company that has high customer concentration, relies entirely on third-party manufacturers, and is controlled by two primary shareholders. Their success hinges on their ability to pivot successfully from COVID-19 testing to a broader, sustainable diagnostic portfolio.